Elanco Animal Health Incorporated (ELAN) on Thursday said it has received conditional approval from the U.S. Food and Drug Administration (FDA) for Credelio Quattro CA1 for the treatment of infestations caused by New World screwworm larvae in dogs.
The conditional approval was based on a study evaluating the efficacy of lotilaner, the active ingredient in Credelio Quattro CA1, against New World screwworm. Published in Parasites & Vectors, the study found that oral administration of lotilaner at the minimum recommended dosage was 100% effective against Cochliomyia hominivorax larvae within 24 hours in naturally infested dogs.
According to the U.S. Department of Agriculture, 14 cases of New World screwworm have been reported within 400 miles of the U.S.-Mexico border, all linked to cattle movement.
ELAN shares were up more than 2% in pre-market after closing at $22,08, down 1.82%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.